EUVIMEDEUVIMED entdecken
Crossref

Glucagon‐Like Peptide‐1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients

Rachel B Kutler, Allison Lin, Lauren Zhang, Paul Trackey, Andrea Rivera-Diaz, Sanja Jelic, Marie-Pierre St-Onge, Yi Cai

Otolaryngology–Head and Neck Surgery · 2026

DOI: 10.1002/ohn.70231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2026. Verfasst von Rachel B Kutler und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Columbia University Vagelos College of Physicians and Surgeons, NewYork-Presbyterian/Columbia Uni…. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are approved to treat obstructive sleep apnea (OSA), yet their use in an OSA population has not been characterized. This study evaluates GLP‐1 RA use in patients presenting to a sleep surgery clinic. Study Design Retrospective.

Setting

Tertiary care institution.

Methods

Patients with OSA who presented to our sleep surgery clinic between October 2023 and March 2025 with available sleep studies were included (n = 384). Demographic data, body mass index (BMI), apnea‐hypopnea index (AHI), OSA history, GLP‐1 RA prescription data, and usage details were collected through chart review. Eligibility for GLP‐1 RA was defined by FDA drug labeling criteria, with diabetes, obesity, or BMI ≥ 27 kg/m² with a weight‐related comorbidity.

Results

The cohort had mean age 53.3 ± 14.8 years, BMI 29.4 ± 5.7 kg/m 2 , and AHI 28.7 ± 24.2 events/h. Most patients (52.1%) had tried CPAP. Among the full cohort (n = 384), 249 patients (64.8%) met FDA‐approved drug labeling criteria for GLP‐1 RA use, and there were 70 (28.1%) current GLP‐1 RA users among eligible patients. Semaglutide (54.8%) and tirzepatide (27.4%) were the most prescribed. The most common reasons for discontinuing or changing GLP‐1 RA types were insurance‐related issues and adverse effects. Among eligible patients, having Medicaid was associated with lower likelihood of using GLP‐1 RAs (adjusted odds ratio 0.25, P = .04) while BMI ≥30 kg/m 2 (adjusted odds ratio 3.45, P < .001) was associated with higher likelihood.

Conclusion

Among sleep surgery clinic patients, a large proportion were eligible for GLP‐1 RA use, and utilization was high compared to that of the general population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Apnea, ObstructiveGlucagon-Like Peptide-1 Receptor AgonistsHumansFemaleRetrospective StudiesMiddle AgedMaleSemaglutideTirzepatideAdultGlucagon-Like PeptidesAged

Stichwörter der Autor:innen

glucagon‐like peptide‐1 receptor agonistsobstructive sleep apneasleep surgery clinic

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideTirzepatideGlucagon-Like Peptides

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Columbia University Vagelos College of Physicians and Surgeons, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York, USA.
  • Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Center of Excellence for Sleep & Circadian Research, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Division of General Medicine, Columbia University Irving Medical Center, New York, New York, USA.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Kutler, R. B., Lin, A., Zhang, L., Trackey, P., Rivera-Diaz, A., Jelic, S., St-Onge, M. P., & Cai, Y. (2026). Glucagon‐Like Peptide‐1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70231

Vancouver

Kutler RB, Lin A, Zhang L, Trackey P, Rivera-Diaz A, Jelic S, et al. Glucagon‐Like Peptide‐1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70231

BibTeX
@article{Kutler2026,
  author = {Kutler, Rachel B and Lin, Allison and Zhang, Lauren and Trackey, Paul and Rivera-Diaz, Andrea and Jelic, Sanja and St-Onge, Marie-Pierre and Cai, Yi},
  title = {Glucagon‐Like Peptide‐1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2026},
  doi = {10.1002/ohn.70231}
}
Kostenlos starten →